Download PDF
Pharmacopsychiatry 2003; 36(2): 61-69
DOI: 10.1055/s-2003-39043
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Antipsychotic Efficacy of the Antidepressant Trimipramine: A Randomized, Double-blind Comparison with the Phenothiazine Perazine

S. Bender1 , H. M. Olbrich2 , W. Fischer3 , C. Hornstein4 , W. Schoene5 , P. Falkai6 , C. Haarmann3 , M. Berger2 , M. Gastpar1 on behalf of the Trimipramine Study Group7
  • 1University of Essen, Clinic for Psychiatry and Psychotherapy, Germany
  • 2University of Freiburg, Clinic for Psychiatry and Psychotherapy, Germany
  • 3Aventis Pharma Deutschland GmbH, Bad Soden, Germany
  • 4Psychiatric Center Nordbaden, Wiesloch, Germany
  • 5Psychiatric Hospital Radebeul, Germany
  • 6University of Bonn, Clinic for Psychiatry and Psychotherapy, Germany
  • 7The following members of the Trimipramine Study Group participated in the study: State Hospital for Psychiatry and Neurology, Arnsdorf: Dr. H. Heilemann, Dr. W. Schoene, Dr. M. Heim; University of Düsseldorf, Clinic for Psychiatry and Psychotherapy: Prof. Dr. W. Gaebel, Prof. Dr. P. Falkai, Dr. M. Eickhoff, PD Dr. A. Klimke, Prof. Dr. Dr. U. Sprick; State Hospital for Psychiatry, Emmendingen: Dr. H. Krzepinski, Dr. P. Hagen; University of Essen, Clinic for Psychiatry and Psychotherapy: Prof. Dr. M. Gastpar, Dr. S. Bender, Dr. M. Baier, K. Ortmann, M. Peveling, Dr. K. Render, M. Schieder, Dr. J. Wolstein; University of Freiburg, Clinic for Psychiatry and Psychotherapy: Prof. Dr. M. Berger, PD Dr. H.M. Olbrich, Dr. E. Dieckmann, Dr. R. Vauth; University of Halle, Clinic for Psychiatry and Psychotherapy: Prof. Dr. A. Marneros, Dr. K. Broich, Dr. B. Langer, Dr. K. Schlote; Psychiatric Hospital Ochsenzoll, Hamburg: Dr. J. Novikov, P. Emrich, Dr. J. Vogt; Psychiatric Center Nordbaden, Wiesloch: Dr. H.D. Middelhoff, Dr. C. Hornstein, Dr. H.E. Bisson, Dr. A. Bätz, J. Gephardt, R. Kösel, Dr. M. Schaupp, Dr. J. Schmidt, Dr. H. Schmitt, Dr. A. Schwarz, A. Will, Dr. B. Zimmer; University of Würzburg, Clinic for Psychiatry and Psychotherapy: Prof. Dr. H. Beckmann, PD Dr. M.H. Lanczik, Dr. F. Frieß.
Further Information

Publication History

Received: 22.5.2001 Revised: 10.5.2002

Accepted: 17.6.2002

Publication Date:
06 May 2003 (online)

Also available at
    Permissions and Reprints

Background: The tricyclic antidepressant trimipramine exhibits several features (e. g., dopaminergic effect, molecular structure similar to a neuroleptic, receptor-binding profile similar to clozapine) that suggest its potential as an antipsychotic medication. The aim of the study was to investigate the antipsychotic potential of trimipramine in a controlled clinical trial comparing its antipsychotic efficacy with that of a neuroleptic. Method: In a German multi-center, randomized, double-blind trial, the antipsychotic efficacy of trimipramine was compared with that of the phenothiazine neuroleptic perazine, using the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impressions (CGI). Antidepressant efficacy of both agents was measured by use of the Bech-Rafaelsen Melancholia Scale (BRMES). Ninety-five patients with acute schizophrenia (DSM-III-R) and a BPRS total score > 40 at baseline were treated with either 300-400 mg trimipramine or 450-600 mg perazine for 5 weeks. Results: Therapeutic equivalence of both treatments (in the dosages used) could not be demonstrated (change in BPRS total score, per-protocol [PP] analysis, one-sided equivalence testing). However, intention-to-treat (ITT) as well as PP analysis showed a statistically significant decrease in the BPRS total scores in both treatment groups (PP: trimipramine, 56.5 ± 9.8 to 44.1 ± 17.9; perazine, 56.4 ± 10.8 to 37.9 ± 12.9). Significant decreases in all BPRS and PANSS subscores as well as CGI results and response rate support the antipsychotic efficacy of trimipramine. The BRMES total scores significantly decreased in both treatment groups without showing a significant difference between the two agents. Trimipramine was better tolerated than perazine and did not elicit extrapyramidal symptoms. Conclusion: Trimipramine failed to exhibit therapeutic equivalence to perazine in the dosages used. However, there was evidence of a substantial antipsychotic effect of trimipramine. It may be a useful medication if depressive symptoms in psychotic patients require antidepressant treatment or if other antipsychotics cannot be administered.

References

  • 1 Akiskal H S, Arana G W, Baldessarini R J, Barreira P J. A clinical report of thymoleptic-responsive atypical paranoid psychoses.  Am J Psychiatry. 1983;  140 1187-1190
    PubMedGoogle Scholar
  • 2 Bech P, Rafaelsen O J. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale.  Acta Psychiatr Scand. 1980;  62[suppl 285] 128-131
    PubMedGoogle Scholar
  • 3 Benkert O, Müller-Siecheneder F, Wetzel H. Negative and depressive symptoms in acute schizophrenic episodes - do they improve under neuroleptic treatment?.  Eur Psychiatry. 1996;  11[suppl 4] 158s-159s
    PubMedGoogle Scholar
  • 4 Berger M, Gastpar M. Trimipramine: a challenge to current concepts on antidepressives.  Eur Arch Psychiatry Clin Neurosci. 1996;  246 235-239
    PubMedGoogle Scholar
  • 5 Declaration of Helsinki, revised version. Hong Kong: The World Medical Association, Inc. 41st Assembly. 
    Google Scholar
  • 6 Eap C B, Bender S, Fischer W, Powell K, Jonzier-Perey M, Cochard N, Berger M, Gastpar M, Baumann P. Steady-state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.  Ther Drug Monit. 2000;  22 209-214
    CrossrefPubMedGoogle Scholar
  • 7 Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M. Trimipramine - an atypical neuroleptic?.  Int Clin Psychopharmacol. 1991;  6 147-153
    PubMedGoogle Scholar
  • 8 Eikmeier G, Muszynski K, Berger M, Gastpar M. High-dose trimipramine in acute schizophrenia: preliminary results of an open trial.  Pharmacopsychiatry. 1990;  23 212-214
    PubMedGoogle Scholar
  • 9 Gaebel W. Perazin - ein klassisches Neuroleptikum aus der Gruppe der piperazinsubstituierten Phenothiazine.  Fundamenta Psychiatrica. 1993;  7 48-57
    PubMedGoogle Scholar
  • 10 Gastpar M. Clinical originality and new biology of trimipramine.  Drugs. 1989;  38 [suppl 1] 43-48
    PubMedGoogle Scholar
  • 11 Gross G, Xin X, Gastpar M. Trimipramine: pharmacological reevaluation and comparison with clozapine.  Neuropharmacology. 1991;  30 1159-1166
    CrossrefPubMedGoogle Scholar
  • 12 Guy W. ECDEU assessment manual for psychopharmacology. Rev ed. Betehsda, MD US Department of Health, Education and Welfare 1976: 217-222
    Google Scholar
  • 13 Hausmann A, Fleischhacker W W. Depression in patients with schizophrenia: prevalence, and diagnostic and treatment considerations.  CNS Drugs. 2000;  14 289-299
    PubMedGoogle Scholar
  • 14 Heinrich K. Die gezielte Symptomprovokation mit monoaminooxydasehemmenden Substanzen in Diagnostik und Therapie schizophrener Psychosen.  Nervenarzt. 1960;  31 507-512
    PubMedGoogle Scholar
  • 15 Hemmeter U, Annen B, Bischof R, Bruderlin U, Hatzinger M, Rose U, Holsboer-Trachsler E. Polysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipramine.  Pharmacopsychiatry. 2001;  34 50-59
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kay S R, Opler L A, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. Toronto; Multi-Health Systems 1992
    Google Scholar
  • 17 Klein D F, Fink M. Psychiatric reaction pattern to imipramine.  Am J Psychiatry. 1962;  119 432-438
    CrossrefPubMedGoogle Scholar
  • 18 Klieser E. Psychopharmakologische Differentialtherapie endogener Psychosen. Stuttgart, New York; Thieme 1990
    Google Scholar
  • 19 Lapierre Y D. A review of trimipramine: 30 years of clinical use.  Drugs. 1989;  38 [suppl 1] 17-24
    PubMedGoogle Scholar
  • 20 Levinson D F, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.  Am J Psychiatry. 1999;  156 1138-1148
    PubMedGoogle Scholar
  • 21 Maj J, Rogoz Z, Skuza G, Margas W. Repeated trimipramine induces dopamine D2/D3 and α1-adrenergic up-regulation.  J Neur Transm Gen Sect. 1998;  105 329-342
    PubMedGoogle Scholar
  • 22 Meltzer H Y. Treatment-resistant schizophrenia - the role of clozapine.  Curr Med Res Opin. 1997;  14 1-20
    PubMedGoogle Scholar
  • 23 Naber D, Krausz M, Lambert M, Bender S. Refractory schizophrenia. In Lader M, Naber D, editors Difficult clinical problems in psychiatry. London; Martin Dunitz 1999: p. 3-22
    Google Scholar
  • 24 Notification of Principles for the Proper Conduct of Clinical Trials (GCP). Drugs made in Germany 1989 32: 21-23
    Google Scholar
  • 25 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psychol Rep. 1962;  10 799-812
    CrossrefPubMedGoogle Scholar
  • 26 Plasky P. Antidepressant usage in schizophrenia.  Schizophr Bull. 1991;  17 649-657
    PubMedGoogle Scholar
  • 27 Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.  J Pharmacol Exp Ther. 1984;  230 94-102
    PubMedGoogle Scholar
  • 28 Riemann D, Vorderholzer U, Cohrs S, Rodenbeck A, Hajak G, Rüther E, Wiegand M H, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Mayer G, Berger M. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.  Pharmacopsychiatry. 2002;  35 165-174
    Google Scholar
  • 29 Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 .  Neuropsychopharmacology. 1992;  7 261-284
    PubMedGoogle Scholar
  • 30 Settle E C, Ayd F J. Trimipramine: twenty years’ worldwide clinical experience.  J Clin Psychiatry. 1980;  41 266-274
    PubMedGoogle Scholar
  • 31 Sokoloff P. Research report on trimipramine. Paris: Unité de neurobiologie et pharmacologie. Centre Paul Broca de l’inserm 1996
    Google Scholar
  • 32 Sonntag A, Frieboes R, Zobel A, Steiger A. Trimipramine in the treatment of psychotic depression.  Pharmacopsychiatry. 1997;  30 215
    PubMedGoogle Scholar
  • 33 Vliegen J. Die Einheitspsychose: Geschichte und Problem. Stuttgart; Enke 1980
    Google Scholar
  • 34 Waldmeier P C. Effects of antidepressant drugs on dopamine uptake and metabolism.  J Pharm Pharmacol. 1982;  34 391-394
    PubMedGoogle Scholar
  • 35 Wetzel H, von Bardeleben U, Holsboer F, Benkert O. Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness.  Fortschr Neurol Psychiatr. 1991;  59 [suppl 1] 23-29
    PubMedGoogle Scholar
  • 36 Wolf R, Dykierek P, Gattaz W F, Maras A, Kohnen R, Dittmann R W, Geuppert M, Riemann D, Berger M. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression.  Pharmacopsychiatry. 2001;  34 60-65
    Article in Thieme ConnectPubMedGoogle Scholar

Dr. Stefan Bender

University of Essen

Dept. of Psychiatry and Psychotherapy

Virchowstr. 174

45147 Essen

Germany

Fax: +49-201-7227-303

Email: stefan.bender@uni-essen.de

      >